Norethindrone Acetate And Ethinyl Estradiol

Ovarian Failure, Hormonal Contraception, Fracture + 16 more
Treatment
20 Active Studies for Norethindrone Acetate And Ethinyl Estradiol

What is Norethindrone Acetate And Ethinyl Estradiol

NorethisteroneThe Generic name of this drug
Treatment SummaryNorethisterone, also known as norethindrone, is a synthetic hormone that mimics the action of the body’s natural progesterone. It is used to treat irregular menstruation and endometriosis and can also be used as part of a hormone replacement therapy or as an oral contraceptive. It was first created in 1951 in Mexico City and was approved for contraceptive use in 1962.
Norinylis the brand name
Norethindrone Acetate And Ethinyl Estradiol Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Norinyl
Norethisterone
1967
345

Effectiveness

How Norethindrone Acetate And Ethinyl Estradiol Affects PatientsNorethisterone is a synthetic medication taken orally to prevent pregnancy or treat hormone-related conditions such as menopause and endometriosis. It works by altering cervical and endometrial function at the pelvic level, as well as blocking hormones released by the pituitary gland that are involved in the development of eggs. Taking norethisterone, or any other type of combined oral contraceptive, is associated with a small increase in the risk of developing breast cancer. Patients who take this medication should be aware of this risk and perform regular self-exams to check for any masses.
How Norethindrone Acetate And Ethinyl Estradiol works in the bodyNorethisterone works by changing the body's hormones to stop pregnancy. It thickens the mucus in the cervix, making it harder for sperm to reach the egg. It also changes the endometrium, making it harder for a fertilized egg to attach. Norethisterone also works on the hypothalamus and anterior pituitary to stop follicle-stimulating and luteinizing hormones from being released, stopping ovulation and corpus luteum development. Lastly, when used as part of hormone replacement therapy, it prevents endometrial hyperplasia and reduces the risk of endometrial cancer.

When to interrupt dosage

The prescribed dosage of Norethindrone Acetate And Ethinyl Estradiol is dependent on the specified situation, such as Atrophic, Fracture and Hormone Replacement Therapy. The quantity of dosage varies, depending on the mode of delivery (e.g. Oral or Tablet) featured in the following table.
Condition
Dosage
Administration
Fracture
, 0.5 mg, 1.0 mg, 0.025 mg/hour, 1.5 mg, 0.35 mg, 0.4 mg, 5.0 mg, 0.014 mg/hour, 0.1 mg, 0.75 mg, 30.0 mg, 0.8 mg, 3.0 mg, 2.25 mg, 2.7 mg, 4.8 mg
Oral, Tablet, , Kit; Tablet, chewable - Oral, Kit, Kit; Tablet, Tablet, film coated, Patch, Transdermal, Intramuscular; Oral; Topical, Tablet - Oral, Patch, extended release, Kit - Oral, Kit; Tablet - Oral, Capsule; Kit, Tablet, chewable, Patch, extended release - Transdermal, Kit; Tablet; Tablet, chewable - Oral, Capsule; Kit - Oral, Tablet, film coated - Oral, Kit; Tablet, film coated, Injection, powder, lyophilized, for suspension; Kit; Tablet - Intramuscular; Oral; Topical, Injection, powder, lyophilized, for suspension; Kit; Tablet, Kit; Tablet, chewable, Capsule, Patch - Transdermal, Kit; Tablet; Tablet, chewable, Capsule, liquid filled; Kit, Capsule, liquid filled; Kit - Oral, Capsule - Oral, Kit; Tablet, film coated - Oral, Tablet, chewable - Oral
Postmenopausal Osteoporosis
, 0.5 mg, 1.0 mg, 0.025 mg/hour, 1.5 mg, 0.35 mg, 0.4 mg, 5.0 mg, 0.014 mg/hour, 0.1 mg, 0.75 mg, 30.0 mg, 0.8 mg, 3.0 mg, 2.25 mg, 2.7 mg, 4.8 mg
Oral, Tablet, , Kit; Tablet, chewable - Oral, Kit, Kit; Tablet, Tablet, film coated, Patch, Transdermal, Intramuscular; Oral; Topical, Tablet - Oral, Patch, extended release, Kit - Oral, Kit; Tablet - Oral, Capsule; Kit, Tablet, chewable, Patch, extended release - Transdermal, Kit; Tablet; Tablet, chewable - Oral, Capsule; Kit - Oral, Tablet, film coated - Oral, Kit; Tablet, film coated, Injection, powder, lyophilized, for suspension; Kit; Tablet - Intramuscular; Oral; Topical, Injection, powder, lyophilized, for suspension; Kit; Tablet, Kit; Tablet, chewable, Capsule, Patch - Transdermal, Kit; Tablet; Tablet, chewable, Capsule, liquid filled; Kit, Capsule, liquid filled; Kit - Oral, Capsule - Oral, Kit; Tablet, film coated - Oral, Tablet, chewable - Oral
hypoestrogenism
, 0.5 mg, 1.0 mg, 0.025 mg/hour, 1.5 mg, 0.35 mg, 0.4 mg, 5.0 mg, 0.014 mg/hour, 0.1 mg, 0.75 mg, 30.0 mg, 0.8 mg, 3.0 mg, 2.25 mg, 2.7 mg, 4.8 mg
Oral, Tablet, , Kit; Tablet, chewable - Oral, Kit, Kit; Tablet, Tablet, film coated, Patch, Transdermal, Intramuscular; Oral; Topical, Tablet - Oral, Patch, extended release, Kit - Oral, Kit; Tablet - Oral, Capsule; Kit, Tablet, chewable, Patch, extended release - Transdermal, Kit; Tablet; Tablet, chewable - Oral, Capsule; Kit - Oral, Tablet, film coated - Oral, Kit; Tablet, film coated, Injection, powder, lyophilized, for suspension; Kit; Tablet - Intramuscular; Oral; Topical, Injection, powder, lyophilized, for suspension; Kit; Tablet, Kit; Tablet, chewable, Capsule, Patch - Transdermal, Kit; Tablet; Tablet, chewable, Capsule, liquid filled; Kit, Capsule, liquid filled; Kit - Oral, Capsule - Oral, Kit; Tablet, film coated - Oral, Tablet, chewable - Oral
Menopause
, 0.5 mg, 1.0 mg, 0.025 mg/hour, 1.5 mg, 0.35 mg, 0.4 mg, 5.0 mg, 0.014 mg/hour, 0.1 mg, 0.75 mg, 30.0 mg, 0.8 mg, 3.0 mg, 2.25 mg, 2.7 mg, 4.8 mg
Oral, Tablet, , Kit; Tablet, chewable - Oral, Kit, Kit; Tablet, Tablet, film coated, Patch, Transdermal, Intramuscular; Oral; Topical, Tablet - Oral, Patch, extended release, Kit - Oral, Kit; Tablet - Oral, Capsule; Kit, Tablet, chewable, Patch, extended release - Transdermal, Kit; Tablet; Tablet, chewable - Oral, Capsule; Kit - Oral, Tablet, film coated - Oral, Kit; Tablet, film coated, Injection, powder, lyophilized, for suspension; Kit; Tablet - Intramuscular; Oral; Topical, Injection, powder, lyophilized, for suspension; Kit; Tablet, Kit; Tablet, chewable, Capsule, Patch - Transdermal, Kit; Tablet; Tablet, chewable, Capsule, liquid filled; Kit, Capsule, liquid filled; Kit - Oral, Capsule - Oral, Kit; Tablet, film coated - Oral, Tablet, chewable - Oral
Ovarian Failure
, 0.5 mg, 1.0 mg, 0.025 mg/hour, 1.5 mg, 0.35 mg, 0.4 mg, 5.0 mg, 0.014 mg/hour, 0.1 mg, 0.75 mg, 30.0 mg, 0.8 mg, 3.0 mg, 2.25 mg, 2.7 mg, 4.8 mg
Oral, Tablet, , Kit; Tablet, chewable - Oral, Kit, Kit; Tablet, Tablet, film coated, Patch, Transdermal, Intramuscular; Oral; Topical, Tablet - Oral, Patch, extended release, Kit - Oral, Kit; Tablet - Oral, Capsule; Kit, Tablet, chewable, Patch, extended release - Transdermal, Kit; Tablet; Tablet, chewable - Oral, Capsule; Kit - Oral, Tablet, film coated - Oral, Kit; Tablet, film coated, Injection, powder, lyophilized, for suspension; Kit; Tablet - Intramuscular; Oral; Topical, Injection, powder, lyophilized, for suspension; Kit; Tablet, Kit; Tablet, chewable, Capsule, Patch - Transdermal, Kit; Tablet; Tablet, chewable, Capsule, liquid filled; Kit, Capsule, liquid filled; Kit - Oral, Capsule - Oral, Kit; Tablet, film coated - Oral, Tablet, chewable - Oral
Hormonal Contraception
, 0.5 mg, 1.0 mg, 0.025 mg/hour, 1.5 mg, 0.35 mg, 0.4 mg, 5.0 mg, 0.014 mg/hour, 0.1 mg, 0.75 mg, 30.0 mg, 0.8 mg, 3.0 mg, 2.25 mg, 2.7 mg, 4.8 mg
Oral, Tablet, , Kit; Tablet, chewable - Oral, Kit, Kit; Tablet, Tablet, film coated, Patch, Transdermal, Intramuscular; Oral; Topical, Tablet - Oral, Patch, extended release, Kit - Oral, Kit; Tablet - Oral, Capsule; Kit, Tablet, chewable, Patch, extended release - Transdermal, Kit; Tablet; Tablet, chewable - Oral, Capsule; Kit - Oral, Tablet, film coated - Oral, Kit; Tablet, film coated, Injection, powder, lyophilized, for suspension; Kit; Tablet - Intramuscular; Oral; Topical, Injection, powder, lyophilized, for suspension; Kit; Tablet, Kit; Tablet, chewable, Capsule, Patch - Transdermal, Kit; Tablet; Tablet, chewable, Capsule, liquid filled; Kit, Capsule, liquid filled; Kit - Oral, Capsule - Oral, Kit; Tablet, film coated - Oral, Tablet, chewable - Oral
Oral Contraceptives
, 0.5 mg, 1.0 mg, 0.025 mg/hour, 1.5 mg, 0.35 mg, 0.4 mg, 5.0 mg, 0.014 mg/hour, 0.1 mg, 0.75 mg, 30.0 mg, 0.8 mg, 3.0 mg, 2.25 mg, 2.7 mg, 4.8 mg
Oral, Tablet, , Kit; Tablet, chewable - Oral, Kit, Kit; Tablet, Tablet, film coated, Patch, Transdermal, Intramuscular; Oral; Topical, Tablet - Oral, Patch, extended release, Kit - Oral, Kit; Tablet - Oral, Capsule; Kit, Tablet, chewable, Patch, extended release - Transdermal, Kit; Tablet; Tablet, chewable - Oral, Capsule; Kit - Oral, Tablet, film coated - Oral, Kit; Tablet, film coated, Injection, powder, lyophilized, for suspension; Kit; Tablet - Intramuscular; Oral; Topical, Injection, powder, lyophilized, for suspension; Kit; Tablet, Kit; Tablet, chewable, Capsule, Patch - Transdermal, Kit; Tablet; Tablet, chewable, Capsule, liquid filled; Kit, Capsule, liquid filled; Kit - Oral, Capsule - Oral, Kit; Tablet, film coated - Oral, Tablet, chewable - Oral
Estrogen Deprivation Symptoms
, 0.5 mg, 1.0 mg, 0.025 mg/hour, 1.5 mg, 0.35 mg, 0.4 mg, 5.0 mg, 0.014 mg/hour, 0.1 mg, 0.75 mg, 30.0 mg, 0.8 mg, 3.0 mg, 2.25 mg, 2.7 mg, 4.8 mg
Oral, Tablet, , Kit; Tablet, chewable - Oral, Kit, Kit; Tablet, Tablet, film coated, Patch, Transdermal, Intramuscular; Oral; Topical, Tablet - Oral, Patch, extended release, Kit - Oral, Kit; Tablet - Oral, Capsule; Kit, Tablet, chewable, Patch, extended release - Transdermal, Kit; Tablet; Tablet, chewable - Oral, Capsule; Kit - Oral, Tablet, film coated - Oral, Kit; Tablet, film coated, Injection, powder, lyophilized, for suspension; Kit; Tablet - Intramuscular; Oral; Topical, Injection, powder, lyophilized, for suspension; Kit; Tablet, Kit; Tablet, chewable, Capsule, Patch - Transdermal, Kit; Tablet; Tablet, chewable, Capsule, liquid filled; Kit, Capsule, liquid filled; Kit - Oral, Capsule - Oral, Kit; Tablet, film coated - Oral, Tablet, chewable - Oral
Therapeutic procedure
, 0.5 mg, 1.0 mg, 0.025 mg/hour, 1.5 mg, 0.35 mg, 0.4 mg, 5.0 mg, 0.014 mg/hour, 0.1 mg, 0.75 mg, 30.0 mg, 0.8 mg, 3.0 mg, 2.25 mg, 2.7 mg, 4.8 mg
Oral, Tablet, , Kit; Tablet, chewable - Oral, Kit, Kit; Tablet, Tablet, film coated, Patch, Transdermal, Intramuscular; Oral; Topical, Tablet - Oral, Patch, extended release, Kit - Oral, Kit; Tablet - Oral, Capsule; Kit, Tablet, chewable, Patch, extended release - Transdermal, Kit; Tablet; Tablet, chewable - Oral, Capsule; Kit - Oral, Tablet, film coated - Oral, Kit; Tablet, film coated, Injection, powder, lyophilized, for suspension; Kit; Tablet - Intramuscular; Oral; Topical, Injection, powder, lyophilized, for suspension; Kit; Tablet, Kit; Tablet, chewable, Capsule, Patch - Transdermal, Kit; Tablet; Tablet, chewable, Capsule, liquid filled; Kit, Capsule, liquid filled; Kit - Oral, Capsule - Oral, Kit; Tablet, film coated - Oral, Tablet, chewable - Oral
Atrophic
, 0.5 mg, 1.0 mg, 0.025 mg/hour, 1.5 mg, 0.35 mg, 0.4 mg, 5.0 mg, 0.014 mg/hour, 0.1 mg, 0.75 mg, 30.0 mg, 0.8 mg, 3.0 mg, 2.25 mg, 2.7 mg, 4.8 mg
Oral, Tablet, , Kit; Tablet, chewable - Oral, Kit, Kit; Tablet, Tablet, film coated, Patch, Transdermal, Intramuscular; Oral; Topical, Tablet - Oral, Patch, extended release, Kit - Oral, Kit; Tablet - Oral, Capsule; Kit, Tablet, chewable, Patch, extended release - Transdermal, Kit; Tablet; Tablet, chewable - Oral, Capsule; Kit - Oral, Tablet, film coated - Oral, Kit; Tablet, film coated, Injection, powder, lyophilized, for suspension; Kit; Tablet - Intramuscular; Oral; Topical, Injection, powder, lyophilized, for suspension; Kit; Tablet, Kit; Tablet, chewable, Capsule, Patch - Transdermal, Kit; Tablet; Tablet, chewable, Capsule, liquid filled; Kit, Capsule, liquid filled; Kit - Oral, Capsule - Oral, Kit; Tablet, film coated - Oral, Tablet, chewable - Oral
Vasomotor System
, 0.5 mg, 1.0 mg, 0.025 mg/hour, 1.5 mg, 0.35 mg, 0.4 mg, 5.0 mg, 0.014 mg/hour, 0.1 mg, 0.75 mg, 30.0 mg, 0.8 mg, 3.0 mg, 2.25 mg, 2.7 mg, 4.8 mg
Oral, Tablet, , Kit; Tablet, chewable - Oral, Kit, Kit; Tablet, Tablet, film coated, Patch, Transdermal, Intramuscular; Oral; Topical, Tablet - Oral, Patch, extended release, Kit - Oral, Kit; Tablet - Oral, Capsule; Kit, Tablet, chewable, Patch, extended release - Transdermal, Kit; Tablet; Tablet, chewable - Oral, Capsule; Kit - Oral, Tablet, film coated - Oral, Kit; Tablet, film coated, Injection, powder, lyophilized, for suspension; Kit; Tablet - Intramuscular; Oral; Topical, Injection, powder, lyophilized, for suspension; Kit; Tablet, Kit; Tablet, chewable, Capsule, Patch - Transdermal, Kit; Tablet; Tablet, chewable, Capsule, liquid filled; Kit, Capsule, liquid filled; Kit - Oral, Capsule - Oral, Kit; Tablet, film coated - Oral, Tablet, chewable - Oral
female castration
, 0.5 mg, 1.0 mg, 0.025 mg/hour, 1.5 mg, 0.35 mg, 0.4 mg, 5.0 mg, 0.014 mg/hour, 0.1 mg, 0.75 mg, 30.0 mg, 0.8 mg, 3.0 mg, 2.25 mg, 2.7 mg, 4.8 mg
Oral, Tablet, , Kit; Tablet, chewable - Oral, Kit, Kit; Tablet, Tablet, film coated, Patch, Transdermal, Intramuscular; Oral; Topical, Tablet - Oral, Patch, extended release, Kit - Oral, Kit; Tablet - Oral, Capsule; Kit, Tablet, chewable, Patch, extended release - Transdermal, Kit; Tablet; Tablet, chewable - Oral, Capsule; Kit - Oral, Tablet, film coated - Oral, Kit; Tablet, film coated, Injection, powder, lyophilized, for suspension; Kit; Tablet - Intramuscular; Oral; Topical, Injection, powder, lyophilized, for suspension; Kit; Tablet, Kit; Tablet, chewable, Capsule, Patch - Transdermal, Kit; Tablet; Tablet, chewable, Capsule, liquid filled; Kit, Capsule, liquid filled; Kit - Oral, Capsule - Oral, Kit; Tablet, film coated - Oral, Tablet, chewable - Oral
Endometriosis
, 0.5 mg, 1.0 mg, 0.025 mg/hour, 1.5 mg, 0.35 mg, 0.4 mg, 5.0 mg, 0.014 mg/hour, 0.1 mg, 0.75 mg, 30.0 mg, 0.8 mg, 3.0 mg, 2.25 mg, 2.7 mg, 4.8 mg
Oral, Tablet, , Kit; Tablet, chewable - Oral, Kit, Kit; Tablet, Tablet, film coated, Patch, Transdermal, Intramuscular; Oral; Topical, Tablet - Oral, Patch, extended release, Kit - Oral, Kit; Tablet - Oral, Capsule; Kit, Tablet, chewable, Patch, extended release - Transdermal, Kit; Tablet; Tablet, chewable - Oral, Capsule; Kit - Oral, Tablet, film coated - Oral, Kit; Tablet, film coated, Injection, powder, lyophilized, for suspension; Kit; Tablet - Intramuscular; Oral; Topical, Injection, powder, lyophilized, for suspension; Kit; Tablet, Kit; Tablet, chewable, Capsule, Patch - Transdermal, Kit; Tablet; Tablet, chewable, Capsule, liquid filled; Kit, Capsule, liquid filled; Kit - Oral, Capsule - Oral, Kit; Tablet, film coated - Oral, Tablet, chewable - Oral
Hormone Replacement Therapy
, 0.5 mg, 1.0 mg, 0.025 mg/hour, 1.5 mg, 0.35 mg, 0.4 mg, 5.0 mg, 0.014 mg/hour, 0.1 mg, 0.75 mg, 30.0 mg, 0.8 mg, 3.0 mg, 2.25 mg, 2.7 mg, 4.8 mg
Oral, Tablet, , Kit; Tablet, chewable - Oral, Kit, Kit; Tablet, Tablet, film coated, Patch, Transdermal, Intramuscular; Oral; Topical, Tablet - Oral, Patch, extended release, Kit - Oral, Kit; Tablet - Oral, Capsule; Kit, Tablet, chewable, Patch, extended release - Transdermal, Kit; Tablet; Tablet, chewable - Oral, Capsule; Kit - Oral, Tablet, film coated - Oral, Kit; Tablet, film coated, Injection, powder, lyophilized, for suspension; Kit; Tablet - Intramuscular; Oral; Topical, Injection, powder, lyophilized, for suspension; Kit; Tablet, Kit; Tablet, chewable, Capsule, Patch - Transdermal, Kit; Tablet; Tablet, chewable, Capsule, liquid filled; Kit, Capsule, liquid filled; Kit - Oral, Capsule - Oral, Kit; Tablet, film coated - Oral, Tablet, chewable - Oral
Low Testosterone
, 0.5 mg, 1.0 mg, 0.025 mg/hour, 1.5 mg, 0.35 mg, 0.4 mg, 5.0 mg, 0.014 mg/hour, 0.1 mg, 0.75 mg, 30.0 mg, 0.8 mg, 3.0 mg, 2.25 mg, 2.7 mg, 4.8 mg
Oral, Tablet, , Kit; Tablet, chewable - Oral, Kit, Kit; Tablet, Tablet, film coated, Patch, Transdermal, Intramuscular; Oral; Topical, Tablet - Oral, Patch, extended release, Kit - Oral, Kit; Tablet - Oral, Capsule; Kit, Tablet, chewable, Patch, extended release - Transdermal, Kit; Tablet; Tablet, chewable - Oral, Capsule; Kit - Oral, Tablet, film coated - Oral, Kit; Tablet, film coated, Injection, powder, lyophilized, for suspension; Kit; Tablet - Intramuscular; Oral; Topical, Injection, powder, lyophilized, for suspension; Kit; Tablet, Kit; Tablet, chewable, Capsule, Patch - Transdermal, Kit; Tablet; Tablet, chewable, Capsule, liquid filled; Kit, Capsule, liquid filled; Kit - Oral, Capsule - Oral, Kit; Tablet, film coated - Oral, Tablet, chewable - Oral
Hot flashes
, 0.5 mg, 1.0 mg, 0.025 mg/hour, 1.5 mg, 0.35 mg, 0.4 mg, 5.0 mg, 0.014 mg/hour, 0.1 mg, 0.75 mg, 30.0 mg, 0.8 mg, 3.0 mg, 2.25 mg, 2.7 mg, 4.8 mg
Oral, Tablet, , Kit; Tablet, chewable - Oral, Kit, Kit; Tablet, Tablet, film coated, Patch, Transdermal, Intramuscular; Oral; Topical, Tablet - Oral, Patch, extended release, Kit - Oral, Kit; Tablet - Oral, Capsule; Kit, Tablet, chewable, Patch, extended release - Transdermal, Kit; Tablet; Tablet, chewable - Oral, Capsule; Kit - Oral, Tablet, film coated - Oral, Kit; Tablet, film coated, Injection, powder, lyophilized, for suspension; Kit; Tablet - Intramuscular; Oral; Topical, Injection, powder, lyophilized, for suspension; Kit; Tablet, Kit; Tablet, chewable, Capsule, Patch - Transdermal, Kit; Tablet; Tablet, chewable, Capsule, liquid filled; Kit, Capsule, liquid filled; Kit - Oral, Capsule - Oral, Kit; Tablet, film coated - Oral, Tablet, chewable - Oral
Birth Control
, 0.5 mg, 1.0 mg, 0.025 mg/hour, 1.5 mg, 0.35 mg, 0.4 mg, 5.0 mg, 0.014 mg/hour, 0.1 mg, 0.75 mg, 30.0 mg, 0.8 mg, 3.0 mg, 2.25 mg, 2.7 mg, 4.8 mg
Oral, Tablet, , Kit; Tablet, chewable - Oral, Kit, Kit; Tablet, Tablet, film coated, Patch, Transdermal, Intramuscular; Oral; Topical, Tablet - Oral, Patch, extended release, Kit - Oral, Kit; Tablet - Oral, Capsule; Kit, Tablet, chewable, Patch, extended release - Transdermal, Kit; Tablet; Tablet, chewable - Oral, Capsule; Kit - Oral, Tablet, film coated - Oral, Kit; Tablet, film coated, Injection, powder, lyophilized, for suspension; Kit; Tablet - Intramuscular; Oral; Topical, Injection, powder, lyophilized, for suspension; Kit; Tablet, Kit; Tablet, chewable, Capsule, Patch - Transdermal, Kit; Tablet; Tablet, chewable, Capsule, liquid filled; Kit, Capsule, liquid filled; Kit - Oral, Capsule - Oral, Kit; Tablet, film coated - Oral, Tablet, chewable - Oral
Osteoporosis
, 0.5 mg, 1.0 mg, 0.025 mg/hour, 1.5 mg, 0.35 mg, 0.4 mg, 5.0 mg, 0.014 mg/hour, 0.1 mg, 0.75 mg, 30.0 mg, 0.8 mg, 3.0 mg, 2.25 mg, 2.7 mg, 4.8 mg
Oral, Tablet, , Kit; Tablet, chewable - Oral, Kit, Kit; Tablet, Tablet, film coated, Patch, Transdermal, Intramuscular; Oral; Topical, Tablet - Oral, Patch, extended release, Kit - Oral, Kit; Tablet - Oral, Capsule; Kit, Tablet, chewable, Patch, extended release - Transdermal, Kit; Tablet; Tablet, chewable - Oral, Capsule; Kit - Oral, Tablet, film coated - Oral, Kit; Tablet, film coated, Injection, powder, lyophilized, for suspension; Kit; Tablet - Intramuscular; Oral; Topical, Injection, powder, lyophilized, for suspension; Kit; Tablet, Kit; Tablet, chewable, Capsule, Patch - Transdermal, Kit; Tablet; Tablet, chewable, Capsule, liquid filled; Kit, Capsule, liquid filled; Kit - Oral, Capsule - Oral, Kit; Tablet, film coated - Oral, Tablet, chewable - Oral
Endometriosis
, 0.5 mg, 1.0 mg, 0.025 mg/hour, 1.5 mg, 0.35 mg, 0.4 mg, 5.0 mg, 0.014 mg/hour, 0.1 mg, 0.75 mg, 30.0 mg, 0.8 mg, 3.0 mg, 2.25 mg, 2.7 mg, 4.8 mg
Oral, Tablet, , Kit; Tablet, chewable - Oral, Kit, Kit; Tablet, Tablet, film coated, Patch, Transdermal, Intramuscular; Oral; Topical, Tablet - Oral, Patch, extended release, Kit - Oral, Kit; Tablet - Oral, Capsule; Kit, Tablet, chewable, Patch, extended release - Transdermal, Kit; Tablet; Tablet, chewable - Oral, Capsule; Kit - Oral, Tablet, film coated - Oral, Kit; Tablet, film coated, Injection, powder, lyophilized, for suspension; Kit; Tablet - Intramuscular; Oral; Topical, Injection, powder, lyophilized, for suspension; Kit; Tablet, Kit; Tablet, chewable, Capsule, Patch - Transdermal, Kit; Tablet; Tablet, chewable, Capsule, liquid filled; Kit, Capsule, liquid filled; Kit - Oral, Capsule - Oral, Kit; Tablet, film coated - Oral, Tablet, chewable - Oral

Warnings

Norethindrone Acetate And Ethinyl Estradiol has eight contraindications and should not be used concurrently with the circumstances specified in the following table.Norethindrone Acetate And Ethinyl Estradiol Contraindications
Condition
Risk Level
Notes
Malignant Neoplasms
Do Not Combine
Thromboembolism
Do Not Combine
Vaginal Hemorrhage
Do Not Combine
Breast Cancer
Do Not Combine
Thrombophilia
Do Not Combine
active liver disease
Do Not Combine
Benign hepatic neoplasm
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Norethisterone may interact with Toxoplasma Infections
There are 20 known major drug interactions with Norethindrone Acetate And Ethinyl Estradiol.
Common Norethindrone Acetate And Ethinyl Estradiol Drug Interactions
Drug Name
Risk Level
Description
Astemizole
Major
The metabolism of Astemizole can be decreased when combined with Norethisterone.
Axitinib
Major
The metabolism of Axitinib can be decreased when combined with Norethisterone.
Cabazitaxel
Major
The metabolism of Cabazitaxel can be decreased when combined with Norethisterone.
Clomipramine
Major
The metabolism of Clomipramine can be increased when combined with Norethisterone.
Copanlisib
Major
The metabolism of Copanlisib can be decreased when combined with Norethisterone.
Norethindrone Acetate And Ethinyl Estradiol Toxicity & Overdose RiskThe lowest toxic dose of oral contraceptives in mice is 6 g/kg and in human women is 42 mg/kg. Even if a child were to take too many oral contraceptives, there have been no reports of serious health issues. However, overdose symptoms may include nausea and vomiting.

Norethindrone Acetate And Ethinyl Estradiol Novel Uses: Which Conditions Have a Clinical Trial Featuring Norethindrone Acetate And Ethinyl Estradiol?

A total of 160 active clinical trials are investigating the potential of Norethindrone Acetate and Ethinyl Estradiol to provide Birth Control, Hormonal Atrophy and Low Testosterone Therapy.
Condition
Clinical Trials
Trial Phases
Osteoporosis
45 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Phase 4, Phase 3
Birth Control
39 Actively Recruiting
Phase 4, Not Applicable, Phase 3, Early Phase 1, Phase 2
Vasomotor System
0 Actively Recruiting
female castration
0 Actively Recruiting
Hot flashes
16 Actively Recruiting
Phase 2, Not Applicable, Phase 1, Phase 4, Early Phase 1
Endometriosis
29 Actively Recruiting
Phase 3, Not Applicable, Early Phase 1, Phase 2, Phase 1, Phase 4
Menopause
0 Actively Recruiting
Therapeutic procedure
0 Actively Recruiting
Hormone Replacement Therapy
0 Actively Recruiting
Endometriosis
1 Actively Recruiting
Phase 4
Hormonal Contraception
0 Actively Recruiting
Atrophic
5 Actively Recruiting
Phase 4, Phase 2, Not Applicable, Early Phase 1
Low Testosterone
18 Actively Recruiting
Phase 1, Phase 2, Phase 4
Postmenopausal Osteoporosis
4 Actively Recruiting
Not Applicable, Phase 4, Phase 3
Estrogen Deprivation Symptoms
0 Actively Recruiting
Oral Contraceptives
0 Actively Recruiting
hypoestrogenism
1 Actively Recruiting
Phase 4
Ovarian Failure
3 Actively Recruiting
Not Applicable, Phase 1
Fracture
0 Actively Recruiting

Norethindrone Acetate And Ethinyl Estradiol Reviews: What are patients saying about Norethindrone Acetate And Ethinyl Estradiol?

5Patient Review
5/5/2017
Norethindrone Acetate And Ethinyl Estradiol for "Change of Life" Signs
I haven't experienced any hot flashes, mood swings, or weight gain since beginning this treatment. If anything, I've lost weight!
5Patient Review
11/7/2011
Norethindrone Acetate And Ethinyl Estradiol for "Change of Life" Signs
I took a break from this treatment for a while, but I really still need it.
5Patient Review
10/17/2012
Norethindrone Acetate And Ethinyl Estradiol for "Change of Life" Signs
This treatment has completely changed my life for the better. No more hot flashes, no more night sweats, and my husband is thrilled.
5Patient Review
2/11/2018
Norethindrone Acetate And Ethinyl Estradiol for "Change of Life" Signs
After being on this medication for a month, I stopped having hot flashes. My cycle started again after three months, which was a bit of a bummer, but other than that I feel great. This has also helped with my hair loss and thinning due to low estrogen levels.
4.3Patient Review
3/3/2016
Norethindrone Acetate And Ethinyl Estradiol for "Change of Life" Signs
So far, this treatment has been great! I no longer have hot flashes or night sweats, and my vaginal dryness is much improved. The only downside is that I've gotten one yeast infection--but it's worth it to be free of the hot flashes.
4.3Patient Review
5/3/2021
Norethindrone Acetate And Ethinyl Estradiol for "Change of Life" Signs
I've been taking this medication for a while now, and it's done wonders for my hot flashes. They stopped almost entirely after only a week of use! I'm also happy to report that I haven't gained any weight since starting the med, which was one of my concerns. The only downside is that I've started having some breakthrough bleeding recently.
4Patient Review
8/26/2013
Norethindrone Acetate And Ethinyl Estradiol for "Change of Life" Signs
I started this treatment when I was 38 and now I'm 48. It's helped with hot flashes and night sweats, but unfortunately not with the vaginal itching and dryness (for which I have to use an expensive cream). Recently, I realized that the weight issues, bloating, and swelling are NOT normal despite having an overall healthy diet.
4Patient Review
11/10/2011
Norethindrone Acetate And Ethinyl Estradiol for "Change of Life" Signs
This treatment has been great for my hot flashes. I can sleep through the night now which is amazing. The only downside is that it's given me a bit of gastric trouble and raised my blood pressure and heart rate. I'm going to discuss changing the dosage with my doctor soon.
4Patient Review
7/2/2022
Norethindrone Acetate And Ethinyl Estradiol for "Change of Life" Signs
Within one week of taking this medication, my menopausal symptoms (hot flashes and night sweats) disappeared. However, the side effects are tough to deal with; I've been experiencing abdominal pain, nausea, and headaches. I'm going to continue taking it in the hopes that my body will adjust to the medication over time because I don't want to go back to having hot flashes and night sweats.
3.7Patient Review
9/26/2016
Norethindrone Acetate And Ethinyl Estradiol for "Change of Life" Signs
I've been taking this for just over three weeks now. I haven't had any hot flashes or night sweats, which is amazing, but I have gained four pounds. Not ideal. I go to the gym regularly, so I know it's not from a sedentary lifestyle. Not sure if I need a lower dose or to stop taking it altogether.
3Patient Review
11/14/2016
Norethindrone Acetate And Ethinyl Estradiol for "Change of Life" Signs
After three weeks of use, my night sweats have stopped. However, I've unfortunately gained five pounds. It's a tough decision to make: whether to keep using the drug and risk gaining more weight or go without it and deal with the night sweats again.
3Patient Review
5/28/2016
Norethindrone Acetate And Ethinyl Estradiol for "Change of Life" Signs
This treatment effectively stopped my hot flashes, but I unfortunately gained twenty pounds in just five months. As a result, I had to discontinue use.
3Patient Review
7/25/2022
Norethindrone Acetate And Ethinyl Estradiol for "Change of Life" Signs
This effectively stopped my hot flashes, but I experienced high anxiety levels as a result, especially in the mornings. I took it for more than a year in the hopes that it would level out, but it didn't.
2.7Patient Review
2/4/2016
Norethindrone Acetate And Ethinyl Estradiol for "Change of Life" Signs
This medication did help to reduce my hot flashes and elevate my mood, however the weight gain was a significant side effect that I wasn't willing to accept.
2.7Patient Review
1/30/2015
Norethindrone Acetate And Ethinyl Estradiol for "Change of Life" Signs
This has helped me with hot flashes, but the weight gain is a big problem.
2.7Patient Review
8/11/2015
Norethindrone Acetate And Ethinyl Estradiol for "Change of Life" Signs
The weight gain was really concerning to me...I tried working out and eating healthy, but I would still gain half a pound every week.
2.3Patient Review
10/15/2013
Norethindrone Acetate And Ethinyl Estradiol for "Change of Life" Signs
After taking this medication for two weeks, I have found that my depression has actually increased. As a result, I will be discontinuing use of the medication.
1.7Patient Review
3/30/2014
Norethindrone Acetate And Ethinyl Estradiol for "Change of Life" Signs
I unfortunately developed breast cancer as a result of this treatment. Please be careful.

Patient Q&A Section about norethindrone acetate and ethinyl estradiol

What is the downside to estradiol norethindrone acetate tablets?

"This medicine comes with risks. It might increase your risk of developing dementia, especially if you're a woman over 65. There's also a chance that it could cause gallbladder disease. If you start experiencing stomach pain, nausea, or vomiting, let your doctor know." - Anonymous Online Contributor

Unverified Answer

What are the side effects of norethindrone acetate and ethinyl estradiol tablets?

"These side effects are usually not permanent.

Possible side effects of this medication include nausea, vomiting, headache, bloating, breast tenderness, swelling of the ankles/feet (fluid retention), or weight change. You may also experience vaginal bleeding between periods (spotting) or missed/irregular periods, especially during the first few months of use. These side effects are usually not permanent." - Anonymous Online Contributor

Unverified Answer

What is norethindrone acetate and ethinyl estradiol used for?

"The combination of these two hormones also makes the cervical mucus thicker, which makes it more difficult for sperm to reach the uterus and fertilize an egg.

This pill contains a combination of two hormones, ethinyl estradiol and norethindrone, which work together to prevent pregnancy. The pill stops a woman's egg from fully developing each month, making it more difficult for sperm to reach the uterus and fertilize an egg." - Anonymous Online Contributor

Unverified Answer

Does norethindrone acetate and ethinyl estradiol cause weight gain?

"Side effects from taking Estrostep can include weight gain from water retention, which is most common in the first one to two months of use." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Clinical Trials for Norethindrone Acetate And Ethinyl Estradiol

Image of Creighton University Osteoporosis Research Center in Omaha, United States.
Phase-Based Progress Estimates
1
Effectiveness
1
Safety

Type 1 Diabeticsfor Osteoporosis

Omaha, NE
18+
Female
Patients with Type 1 Diabetes Mellitus have a higher risk of low-trauma (osteoporotic) fracture that is 7-12 times higher than non-diabetics. The bone density of people with Type 1 Diabetes is higher at the time of fracture than in non-diabetics. This suggests the presence of underlying bone tissue mechanical defects. The potential benefits to participants would be knowledge gained about their bone density and the results of laboratory tests. On a wider scale, there may be general benefits to society because the knowledge gained from this study may help better understand the effects of diabetes on bone health
Recruiting
Senior-friendly
Creighton University Osteoporosis Research CenterMohammed Akhter, PhD
Image of University of Colorado Anschutz Medical Center, Clinical Translational Research Center and Exercise Research Laboratory in Aurora, United States.
Phase-Based Progress Estimates
1
Effectiveness
1
Safety

No Exercise Plus MitoQfor Menopause

Aurora, CO
50 - 120
Female
An impairment in vascular function can lead to the development of age-associated cardiovascular disease (CVD), the leading cause of death in postmenopausal women. Regular aerobic exercise (AE) benefits vascular function in older men by reducing oxidative stress, however, similar AE training improvements are diminished or absent in postmenopausal women. not using estrogen-based hormone therapy. Vascular function and oxidative stress are improved with AE training in postmenopausal women treated with E2, suggesting an essential role of E2 in vascular adaptations to AE in women. Clinical use of E2 is contraindicated for this purpose, thus establishing alternative pharmacological approaches that could be administered as a substitute for E2 to improve AE signaling for vascular benefits and reducing CVD risk in E2-deficient postmenopausal women is biomedically important. The mitochondrial-targeted antioxidant MitoQ may be an alternative to E2 for restoring AE benefits in E2-deficient postmenopausal women given its recently established effectiveness for reducing oxidative stress and improving vascular function in that population. Accordingly, the overall aim of this application is to assess the efficacy of a 12-week randomized controlled trial of moderate intensity AE training combined with oral MitoQ (20 mg/d) compared to AE+oral placebo (PL) or No AE+MitoQ on vascular vasodilatory function (brachial artery flow-mediated dilation; FMD) in healthy E2-deficient postmenopausal women. Insight into the causes for the improvement related to molecules (e.g., nitric oxide) that promote vasodilation, mitochondrial function, oxidative stress, and the influence of "circulating factors" will also be obtained. We hypothesize that AE+MitoQ will improve both FMD > AE+PL and > No AE+MitoQ, and that No AE+MitoQ will improve FMD > AE+PL. The greater improvements in endothelial function with AE+MitoQ vs. both AE+PL and No AE+MitoQ, and with No AE+MitoQ vs. AE+PL will be mediated by greater improvements in nitric oxide production, mitochondrial function, and mitochondrial and oxidative stress linked, at least in part, to changes in "circulating factors". The expected results from this study will establish the efficacy of MitoQ for restoring AE-vascular signaling in E2-deficient postmenopausal women and will provide the foundation for development of evidence-based guidelines for sex-specific AE programs for improving vascular health and preventing CVD in postmenopausal women.
Phase < 1
Waitlist Available
University of Colorado Anschutz Medical Center, Clinical Translational Research Center and Exercise Research LaboratoryKerrie L Moreau, PhD
Have you considered Norethindrone Acetate And Ethinyl Estradiol clinical trials? We made a collection of clinical trials featuring Norethindrone Acetate And Ethinyl Estradiol, we think they might fit your search criteria.
Image of University of Utah in Salt Lake City, United States.
Phase-Based Progress Estimates
1
Effectiveness
1
Safety

Etonogestrel Contraceptive Implantfor Inflammatory Bowel Disease

Salt Lake City, UT
18 - 45
Female
Of the 1.8 million U.S. women with inflammatory bowel diseases (IBD), over half of those who are premenopausal suffer from cyclical menstrual-related IBD symptoms, regardless of how well their disease is controlled. Despite the significant impact that cyclical IBD symptoms have on quality of life, evidence about how to alleviate these symptoms is lacking. In other chronic conditions which are hormonally influenced, such as epilepsy, hormonal contraception may be used to favorably impact disease-related symptoms associated with menses and improve quality of life. Long acting reversible contraception, including the etonogestrel (ENG) contraceptive implant and levonorgestrel (LNG) intrauterine device (IUD), are the most effective contraceptive options with excellent safety profiles and are highly desired if access barriers are removed, thus ideal for study in this population. In our previous cross-sectional study, 47% of the levonorgestrel (LNG) IUD users reported improvement in their cyclical IBD symptoms, but ENG implant use was uncommon and prospective data on the effect of either the IUD or implant on symptoms remain lacking. In order to design a future comparative effectiveness trial on the effect of the ENG implant and LNG IUD on menstrual-related IBD symptoms, the investigators propose this pilot randomized controlled trial with a participant-preference arm to define a feasible study design and recruitment plan, determine metrics to differentiate between non-menstrual and menstrual-related IBD symptoms, and explore the potential role of use of inflammatory markers in future trials. The investigators will recruit participants from the University of Utah IBD Center and clinics and through social media ads. Total study commitment will be ~8 months which includes two spontaneous menstrual cycles prior to contraceptive initiation and then six months of follow-up. Study activities will include daily and weekly text message surveys, as well as blood draws and fecal samples for inflammatory markers commonly used for IBD management. Our aims include: (1) To determine acceptability of randomization to the ENG contraceptive implant or 52mg-LNG IUD and in those who decline, acceptability of participation in a participant-preference arm, (2) To obtain estimates of means and standard deviations in established IBD symptom scales (Harvey Bradshaw and partial Mayo) and IBD quality of life measures across the phases of two menstrual cycles and then for 6 months after contraceptive method initiation, and (3) To obtain preliminary estimates of inflammatory marker variation across menstrual phases and pre- and post- contraceptive initiation. This pilot will inform a future trial design and this line of inquiry will allow for an adjuvant approach for IBD symptom management that is sex-specific and addresses both concerns for hormonal triggers and the need for highly-effective contraception for those who desire it.
Waitlist Available
Has No Placebo
University of UtahLori Gawron
Have you considered Norethindrone Acetate And Ethinyl Estradiol clinical trials? We made a collection of clinical trials featuring Norethindrone Acetate And Ethinyl Estradiol, we think they might fit your search criteria.
Have you considered Norethindrone Acetate And Ethinyl Estradiol clinical trials? We made a collection of clinical trials featuring Norethindrone Acetate And Ethinyl Estradiol, we think they might fit your search criteria.